PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$12.24
-0.04 (-0.33%)
▼
5d:
-8.72%
30d:
-25.32%
90d:
-24.54%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PHAR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PHAR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.13
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $12.24, which is considered slightly low relative to its 30-day fair value range of $12.23 to $15.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 42.3) compared to its historical average (238.5). Remarkably, the market is currently pricing in an annual earnings decline of 43.8% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a downtrend. The price is currently testing key support at $12.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+179.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PHAR is in a downtrend. The price is currently testing key support at $12.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+179.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$12.23 -
$15.66
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 179.7% below Wall St target ($34.35)
- CAUTION: Recommendation downgraded due to -8.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$12.23 -
$15.66
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$12.19
Resistance Level
$13.77
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.30
Wall Street Target
$34.35
(+179.7%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-43.8% cheaper
PE vs Historical
42.3 vs 238.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-43.8%
(market-implied from PE analysis)
1-Year Target
$11.05
(-10%)
2-Year Target
$9.95
(-19%)
3-Year Target
$8.95
(-27%)
3-Yr Target (if PE normalizes)
(PE: 42→239)
$50.47
(+311%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 42.3, Growth: 44.9%)
$37.38
(+204%)
Base:
(SPY PE: 21.9, Growth: 44.9%)
$19.36
(+58%)
Bear:
(PE: 18.6, Growth: 44.9%)
$16.46
(+34%)
📈
Valuation based on Current Earnings
Forward PE: 28.09 | Forward EPS (Implied): $0.49
Bull Case
$16.49
(+21%)
Analyst growth 15.0%, PE expands to 29.5
Base Case
$13.66
(0%)
Market implied 0.0%, PE stable at 28.1
Bear Case
$10.45
(-24%)
Severe decline -15.0%, PE contracts to 25.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 42.3 to 238.5
Stabilization Target:
$69.24
(+463.8%)
PE Expansion Potential:
+463.8%
Share & Embed Analysis
Last updated: June 03, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
